STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Virus Studies Review Article

Bacteriophages- A New Frontier in Medicine

  1. Aryamaan Sethi Government Medical College, Sangareddy
  2. Madhu Y Department of Pharmacology, Government Medical College, Suryapet
  3. Aishwarya Mantri Department of Pathology, Pacific Institute of Medical Sciences, Udaipur
  4. Shubham Jaju Department of Pharmacology, Pacific Institute of Medical Sciences, Udaipur

Abstract

Bacteriophages, or phages, are viruses that specifically target and infect bacteria, offering an innovative alternative to traditional antibiotic treatments, especially in the face of rising antibiotic resistance. The resurgence of phage therapy has been driven by the increasing prevalence of multidrug-resistant bacterial strains and the slowdown in the development of new antibiotics. Phages, unlike antibiotics, target specific bacterial strains, reducing the impact on the natural microbiota and potentially offering a safer and more precise treatment. However, the clinical application of bacteriophages presents several challenges. One major issue is bacterial resistance to phages, similar to antibiotic resistance. Bacteria can evade phages by altering receptors or employing defense mechanisms to block phage DNA injection. Another concern is phage-induced lysis, which may release harmful bacterial toxins into the body. Additionally, phages can transmit genetic material, such as virulence factors or antibiotic resistance genes, to the microbiome, which brings up potential safety issues. Another challenge is the immune system's response to bacteriophages, as the body might identify them as foreign agents and remove them before they can perform their intended function. The specificity of phages, while advantageous in reducing harm to non-target bacteria, complicates treatment, requiring personalized phage cocktails tailored to each infection, making standardization and large-scale production difficult. Despite these hurdles, bacteriophage therapy holds significant promise as a complementary or alternative approach to antibiotics, particularly in addressing infections that no longer respond to conventional treatments. Ongoing research and clinical trials are critical to understanding and mitigating the limitations of phage therapy to integrate it successfully into modern medical practice​.

Keywords

References (15)

  1. Łusiak-Szelachowska M, Weber-Dąbrowska B, Żaczek M, Borysowski J, Górski A. The Presence of Bacteriophages in the Human Body: Good, Bad or Neutral? Microorganisms. 2020;8(12):2012. doi:10.3390/microorganisms8122012
  2. Principi N, Silvestri E, Esposito S. Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections. Frontiers in Pharmacology. 2019;10. doi:10.3389/fphar.2019.00513
  3. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. International Journal of Antimicrobial Agents. 2019;53(1):16-21. doi:10.1016/j.ijantimicag.2018.09.004
  4. Kasman LM, Porter LD. Bacteriophages. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
  5. Ptashne M. Lambda's switch: lessons from a module swap. Curr Biol. 2006;16(12)–62.
  6. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. International Journal of Antimicrobial Agents. 2019;53(1):16-21. doi:10.1016/j.ijantimicag.2018.09.004
  7. Domingo-Calap P, Delgado-Martínez J. Bacteriophages: Protagonists of a Post-Antibiotic Era. Antibiotics. 2018;7(3):66. doi:10.3390/antibiotics7030066
  8. Bogovazova GG, Voroshilova NN, Bondarenko VM. The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol. 1991;(4):5–8.
  9. Bogovazova GG, Voroshilova NN, Bondarenko VM, Gorbatkova GA, Afanas'eva EV, Kazakova TB, et al. Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol. 1992;(3):30–3.
  10. Reindel R, Fiore CR. Phage therapy: considerations and challenges for development. Clin Infect Dis [Internet]. 2017;64(11):1589–90. Available from: https://academic.oup.com/cid/article/64/11/1589/3058816
  11. Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials. Annual Review of Virology. 2015;2(1):599-618. doi:10.1146/annurev-virology-100114-054915
  12. Seed KD. Battling Phages: How Bacteria Defend against Viral Attack. PLOS Pathogens. 2015;11(6):e1004847. doi:10.1371/journal.ppat.1004847
  13. Torres-Barceló C. Phage Therapy Faces Evolutionary Challenges. Viruses. 2018;10(6):323. doi:10.3390/v10060323
  14. Kaźmierczak Z, Piotrowicz A, Owczarek B, Hodyra K, Miernikiewicz P, Lecion D, et al. Molecular imaging of T4 phage in mammalian tissues and cells. Bacteriophage. 2014;4(2):e28364. doi:10.4161/bact.28364
  15. Srivastava AS, Kaido T, Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. Journal of Virological Methods. 2004;115(1):99-104. doi:10.1016/j.jviromet.2003.09.009